Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.7% Higher – Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price traded up 7.7% during mid-day trading on Friday . The company traded as high as $81.47 and last traded at $82.3290. 363,875 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 906,263 shares. The stock had previously closed at $76.45.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a research note on Monday, March 9th. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday. Wedbush upped their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Trading Up 7.2%

The firm has a fifty day simple moving average of $87.15 and a two-hundred day simple moving average of $64.95. The stock has a market cap of $4.48 billion, a PE ratio of -19.87 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Insider Activity

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at $362,480. This trade represents a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Ryan Savitz sold 8,224 shares of the firm’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the sale, the executive vice president directly owned 8,224 shares in the company, valued at approximately $738,844.16. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 149,121 shares of company stock worth $12,635,454. Insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently modified their holdings of DNTH. Wellington Management Group LLP raised its holdings in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after buying an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after buying an additional 1,499,931 shares in the last quarter. State Street Corp raised its holdings in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after buying an additional 836,571 shares in the last quarter. Braidwell LP purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at about $32,859,000. Finally, Polar Capital Holdings Plc purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at about $29,434,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.